1. THIS IS AN ANNOUNCEMENT AND NOT A CIRCULAR OR PROSPECTUS OR EQUIVALENT DOCUMENT FOR THE PURPOSES OF THE UK PROSPECTUS REGULATION RULES OR THE EU PROSPECTUS REGULATION. Click here for available international numbers. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency as well as the first and only approved Factor Xa inhibitor reversal agent. Report all contractual actions, including modifications, that have a face value, excluding unexercised options, of more than $ 7.5 million. Adrian Kemp Sources of information and bases of calculation. 29 Jun 2010. (ix) The volume weighted average price of an Alexion Share is derived from Bloomberg by reference to the volume weighted average price over the last 30 Alexion trading days up to 11 December 2020 (being the last Business Day prior to announcement of an offer for Alexion). If you are in any doubt, you should not continue to seek to access this area of the website. Goldman Sachs Bank USA is acting as lead debt financing underwriter. Nothing contained in this area of the website should be construed as a profit estimate or profit forecast and no statement in this area of the website should be interpreted to mean that earnings per share of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share of AstraZeneca or Alexion. Members of Alexion's current senior management team will lead the future rare-disease activities. Morgan Stanley & Co. International plc ("Morgan Stanley”) and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) (“J.P. As at the date of this announcement, JOES has a paid -up share capital consisting of 100 ordinary shares of S$ 1 each. Alexion's leading expertise in complement biology will accelerate AstraZeneca's growing presence in immunology. Evercore Partners International LLP (“Evercore”), and Centerview Partners UK LLP (“Centerview Partners”) are acting as lead financial advisers. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company. The acquisition is expected to realise recurring run-rate pre-tax synergies of c.$500m per year from the combined Group, generated from commercial and manufacturing efficiencies as well as savings in central costs, with full run-rate expected to be achieved by end of the third year following completion of the acquisition. Date of Board Meeting. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases. 1. These forward-looking statements include all matters that are not historical facts and involve predictions. For Media enquiries, Megan Goulart, +18573388634, and for Investor Relations, Chris Stevo, +18573389309. Any forward-looking statements reflect AstraZeneca's and Alexion's current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to AstraZeneca's or Alexion's results of operations, financial position, liquidity, prospects, growth or strategies and the industries in which they operate. The success of the franchise is demonstrated by the effective transition of over 70% of PNH patients from Soliris to Ultomiris in less than two years of launch in its key markets, including the US, Japan and Germany, as well as the strong pipeline of additional indications for Ultomiris. Announcement Acquisition of own shares Athens, Greece - December 28, 2020 - Mytilineos S.A. (MYTILINEOS) announces that, according to the resolution of its Extraordinary Shareholders' Meeting dated 27.03.2020, on 23.12.2020, acquired through the Athens Exchange 20,000 own shares at a weighted average price €11.6521 per share, of an aggregate value €233,042.25. It is important to spend time reviewing all of these considerations before announcing because of the importance of your transaction being successful in the long term.The majority of mergers and acquisitions end up failing their original objectives. Announcing the good news in an acquisition announcement letter raises the morale of not only your customers but the employees as well. The boards of directors of both Alexion and AstraZeneca have unanimously approved the proposed acquisition and resolved to recommend that their respective shareholders vote in favour of it. acquisition of the Balance Sale Shares, and the terms of such acquisition,shall be conditional upon the outcome of such investigation (the “Outcome”). The combined company is expected to deliver double-digit average annual revenue growth through 2025. Tuesday, February 21, 2012] [NAME, COMPANY AND ADDRESS, ex. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Forward-looking statements may and often do differ materially from actual results. AstraZeneca is not responsible for the privacy policy of any third party websites. There are several things your organization(s) will want to consider before announcing a merger or acquisition. The information contained in this website is made available in good faith and for information purposes only and is subject to the terms and conditions set out below. Alexion's franchise includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. It has been prepared solely for the proposed acquisition referred to in this announcement. Immediately earnings-accretive and value-enhancing acquisition, in line with stated capital-allocation priorities. This acquisition … Unless otherwise stated: financial information relating to AstraZeneca has been extracted or derived from the audited results for the twelve months ended 12 December 2019; and financial information relating to Alexion has been extracted or derived from the audited results for the twelve months ended 31 December 2019, and the unaudited results for the nine months ended 30 September 2020. Interim Results for 2010. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this announcement may not conform precisely with the total figure given. Postal Code : XXXXXXX Phone Number : 0000 - 123456789 E-mail ID : sendersname@companywebsite.com Date : Reference : TO : Addressee's Name, Designation, The Company's Name, The complement cascade is pivotal to the innate immune system. •      on the basis of the issued and to be issued share capital of Alexion (as set out in paragraph (ii) above). Wednesday, June 11, 1998] [NAME, COMPANY AND ADDRESS, ex. I agree to be bound by the terms of this notice. These forward looking statements include all matters that are not historical facts and involve predictions. Epic Games, the developer and publisher of Fortnite, maker of Unreal Engine, and operator of the Epic Games Store has acquired RAD Game Tools. To the fullest extent permitted by applicable law, Goldman Sachs International, Goldman Sachs Bank USA and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any statement contained therein. Alexion has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. This announcement may include statements that are or may be deemed to be forward-looking statements. I am incredibly proud of what our organisation has accomplished and am grateful to our employees for their contributions. The cash and ADS consideration represents an c.45% premium to Alexion shareholders based on the closing stock price of Alexion on 11 December 2020 and a c.43% premium, based on the 30-day volume-weighted average closing stock price of $122.04 before this announcement. Announcement of Acquisition of HOPES Corporation. All contents remain copyrighted and reserved. AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion's portfolio. Company Acquisition Announcement. Are you the principal of an RIA, Hybrid RIA, or broker dealer IAR? Goldman Sachs International, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and Goldman Sachs Bank USA, which is authorised and regulated by the Board of Governors of the Federal Reserve System (Federal Reserve Board), the FDIC and the New York State Department of Financial Services, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. Nothing in this announcement should be construed as a profit estimate or profit forecast. The new business name for the Plant Operations is – MARWOOD INTERNATIONAL – Plant 6 effective February 1, 2020. Welltel are pleased to announce the acquisition of ATS, a leading provider of Phone Systems and telecoms services to Enterprise and Government bodies in Ireland. AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. Announce the merger, acquisition, or restructuring up front. The combined companies will bring together two rapidly converging, patient-centric models of care delivery with combined strengths in immunology, biologics, genomics and oligonucleotides to drive future medicine innovation. The Alexion proxy statement is also expected to be published in the first half of 2021. You are attempting to enter the area of this website that is designated for the publication of documents and information in connection with the proposed acquisition by AstraZeneca PLC (AstraZeneca) and Alexion Pharmaceuticals, Inc. (Alexion) (the Transaction). Economic, competitive, governmental, technological and other factors that may affect AstraZeneca’s and Alexion’s operations are discussed in the section entitled “Risk Factors,” in each of AstraZeneca’s Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion’s Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings made with the SEC. AstraZeneca remains committed to maintaining a strong investment-grade credit rating. •      6,202,972 Alexion Shares which may be issued on or after the date of this announcement to satisfy the exercise of stock options and restricted and performance stock awards outstanding under the Alexion Share Plans, estimated based on the total consideration of $175 per Alexion share and calculated in accordance with the Treasury Stock Method. If you are resident or located in a country that renders the accessing of this area of the website or parts thereof illegal, whether or not subject to making certain notifications or taking other action, you should not view this area of the website. Freshfields Bruckhaus Deringer is acting as legal counsel. If you would like to view this area of the website, please read this notice carefully. As of 30 September 2020, Alexion had gross assets of $17.5bn. Enhanced revenue growth, operating margin and cash-flow generation. Alexion's immunology expertise extends to other targets in the complement cascade beyond C5 as well as additional modalities, with its deep pipeline including Factor D small-molecule inhibitors of the alternative pathway of the complement system, an antibody blocking neonatal Fc receptor (FcRn)-mediated recycling, and a bi-specific mini-body targeting C5, among others. Announcement of Acquisition. John Smith XYZ Inc. 1234 First Street Suite 567 Anycity, Anystate 85245] Dear Valued Customer: We are pleased to announce that we have recently acquired [DESCRIBE BUSINESS ACQUIRED, ex. Industry-leading revenue growth; enhanced geographical presence and broad coverage across primary, specialised and highly specialised care. By Emily July 6, 2017 October 25th, 2017 Business insight, News, Welltel News. This transaction marks the start of an exciting new chapter for Alexion. The date at which a company will announce the details regarding an issue of debt or equity. Company Secretary Information about the directors and executive officers of Alexion and their ownership of Alexion shares is set forth in the definitive proxy statement for Alexion’s 2020 special meeting of shareholders, as previously filed with the SEC on March 26, 2020. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. (a) Public Announcement. Reference: Announcement of Acquisition of Tranor Industries LLC Detroit USA . In particular, you should not forward or transmit the announcements, information or documents contained therein to Canada, Australia, Japan or South Africa or to any other jurisdiction where it would be unlawful to do so. The documents included in this area of the website speak only at the specified date of the relevant document and neither AstraZeneca nor any of its affiliated companies has or accepts any responsibility or duty to update such documents (other than to the extent such duty arises as a matter of law).